Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.54 |
| ▸ | MMP9 | P14780 | 4/20 | 0.54 |
| ▸ | MMP8 | P22894 | 3/20 | 0.54 |
| ▸ | MMP12 | P39900 | 3/20 | 0.54 |
| ▸ | MMP14 | P50281 | 3/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.54 |
| ▸ | CASP2 | P42575 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15783568 | 0.95 | CASP2 (0.56) | MMP2MMP9MMP8MMP12MMP14 | |
| Hydrochloric Acid SCHEMBL23834203 | 0.94 | CASP2 (0.54) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL15783567 | 0.93 | NOD1 (0.62) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL14519219 | 0.90 | MMP2 (0.52) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL14118034 | 0.88 | FOLH1 (0.51) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL14253093 | 0.87 | CASP2 (0.49) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL14438880 | 0.87 | NOD1 (0.71) | NOD1GLP1R | |
| SCHEMBL17479995 | 0.86 | NOD1 (0.62) | NOD1CASP2GLP1RNAAA | |
| SCHEMBL12580525 | 0.85 | FOLH1 (0.42) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL17479992 | 0.84 | NOD1 (0.61) | NOD1CASP2GLP1RNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165313-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165313-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | EGFR, VEGFA, ERBB2 | MMP2 1714/4885MMP9 2643/4885MMP8 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.